Skip to main content
. 2021 Jan 7;22(2):532. doi: 10.3390/ijms22020532

Figure 2.

Figure 2

Overview of PPIs-based drug repurposing. SARS-CoV-2 interactomes are generated by affinity purification Mass Spectrometry (AP-MS) or by Proximity-Dependent Biotin Labeling (BioID). Interactions between SARS-CoV-2 viral baits proteins and host proteins targetable by already approved drugs are selected. Next, druggable host targets are analysed by biochemical and cell-based assays for antiviral activity. Selected lead compounds with in vitro anti-viral efficacy are then tested for in vivo efficacy on COVID-19 patients.